HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4⁺ T cells.

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

1. Brodsky F. 1984. Immunogenetics 19:179.
2. Robbins P, et al. 1987. Human Immunol. 18:301.
3. Stites D, et al. 1986. Clin. Immunol. Immunopathol. 38:161.
4. Warnke R, et al. 1980. J. Histochem. Cytochem. 28:771. (IHC)
5. Engleman E, et al. 1981. P. Natl. Acad. Sci. USA 78:1791. (IHC)
6. Zipf T, et al. 1981. Cancer Res. 41:4786.
7. Goodier M, et al. 2000. J. Immunol. 165:139. (Depletion)
8. Esser M, et al. 2001. J. Virol. 75:6173. (IP, WB)
9. Kalka-Moll WM, et al. 2002. J. Immunol. 169:6149. (Block)
10. Wang RF, et al. 1999. Science 284:1351. (Block)
11. Zaba LC, et al. 2007. J. Exp. Med. 204:3183. PubMed
12. Fujita H, et al. 2009. P. Natl. Acad. Sci. USA 106:21795. PubMed
13. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
14. Goncalves RM, et al. 2010. Infect. Immun. 78:4763. PubMed
15. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
16. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
17. Stein R, et al. 2011. Leuk. Lymphoma 52:273.
18. Galkowska H, et al. 1996. Vet. Immunol. Immunopathol. 53:329.
19. Moro M, et al. 2005. BMC Immunol. 6:24.
20. Lauterbach N, et al. 2014. Mol Immunol. 59:19. PubMed